Why Your BMI Determines Wegovy Eligibility In The UK
BMI For Wegovy: Understanding UK Prescription Requirements
The BMI requirements for Wegovy in the UK are clearly defined by MHRA licensing and NICE guidance TA875. Adults qualify for Wegovy with a BMI of 30 or above, or a BMI of 27 or above when accompanied by weight-related health conditions such as type 2 diabetes, high blood pressure, or sleep apnoea. This prescription-only medicine requires careful clinical assessment to ensure suitability and safety. When you buy Wegovy online through EverydayMeds, our clinical team verifies your BMI eligibility as part of the comprehensive assessment process.
Adolescents aged 12 and above can also access Wegovy, provided they weigh over 60kg and have a BMI corresponding to 30 or above in adults. The BMI thresholds for Wegovy ensure that this powerful GLP-1 treatment reaches those who will benefit most from its appetite-suppressing effects. Our online consultation specifically addresses BMI calculations and weight-related comorbidities, making the qualification process transparent and straightforward for UK patients.
Wegovy Pricing Structure: BMI-Based Dosing From £79.99
Understanding BMI for Wegovy extends to the pricing structure, as your treatment journey follows a mandatory dose escalation schedule regardless of starting BMI. New customers begin with the 0.25mg starter dose at £79.99 (with code FIRST40 applied at checkout), progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose (£209.99). Our Intro Duo bundle (0.25mg & 0.5mg) costs £169.99, providing your first two months of treatment with convenient single delivery. Returning customers benefit from code DOSE25 at checkout, with all prices including prescriber consultation and next-day cold-chain delivery.
The BMI requirements for Wegovy don't affect your pricing - whether you qualify with BMI 27 plus comorbidities or BMI 35, you follow the same dose escalation protocol. Our Gentle Start Trio bundle (0.25mg, 0.25mg, 0.5mg) at £269.99 allows extended time at the lowest dose for those experiencing initial side effects. The Ultimate Stability Trio provides three months of maintenance 2.4mg supply for £649.99, ensuring consistent treatment once you've reached your optimal dose after meeting the BMI for Wegovy requirements.
Clinical Evidence: BMI Impact On Wegovy Effectiveness
In clinical trials, patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved remarkable results across different BMI ranges. The landmark STEP 1 trial (Wilding et al., NEJM, 2021) demonstrated approximately 15% average weight loss at 68 weeks versus 2.4% with placebo. STEP 3 showed approximately clinically studied weight loss when combined with intensive behavioural therapy.
The BMI for Wegovy qualification criteria are based on this robust clinical evidence, with STEP 5 demonstrating sustained weight loss of approximately 15.2% at two years. The SELECT trial revealed a 20% reduction in major cardiovascular events (HR 0.80), highlighting benefits beyond BMI reduction for patients who meet the BMI for Wegovy prescription criteria.
How Wegovy Works: GLP-1 Mechanism Across BMI Ranges
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, working effectively regardless of your starting BMI. Once injected weekly via the convenient FlexTouch pen, Wegovy reduces appetite and promotes feelings of fullness after smaller meals. The medication works on brain appetite centres, potentially reducing food cravings and making it easier to maintain the reduced-calorie diet required alongside treatment. This mechanism explains why BMI for Wegovy requirements focus on clinical need rather than specific BMI numbers. The prescription-only medicine supports sustainable weight management by addressing the biological drivers of appetite and satiety. Your response to Wegovy depends more on individual physiology than starting BMI, though higher BMI patients may see more dramatic absolute weight loss results.
Simple Online Ordering Process For BMI-Qualified Patients
Once you understand the BMI for Wegovy requirements, ordering online through EverydayMeds takes just minutes. Complete our 3-minute clinical assessment covering your BMI calculation, weight history, current medications, and any relevant health conditions. Our specialist prescribers review your application within 3 working days (or 24 hours with express service), ensuring you meet the BMI for Wegovy criteria safely. Upon approval, your genuine Novo Nordisk Wegovy dispatches via next-day cold-chain delivery, arriving temperature-controlled and ready for immediate use. The entire process from BMI assessment to receiving your first Wegovy pen typically takes under a week, with ongoing support available throughout your treatment journey.
Storage And Practical Considerations For Wegovy Treatment
Regardless of your qualifying BMI for Wegovy, proper storage ensures medication effectiveness and safety. Store unused Wegovy pens in the fridge at 2-8°C, though they remain stable for up to 6 weeks at room temperature below 30°C once removed. This storage flexibility makes Wegovy ideal for travel compared to other weight management injections. The FlexTouch pen system requires no mixing or preparation - simply attach a new needle, dial your dose, and inject subcutaneously once weekly. Dose escalation follows the same schedule for all patients meeting BMI for Wegovy requirements, starting at 0.25mg and increasing monthly until reaching the 2.4mg maintenance dose. Most patients find injection sites on the thigh, abdomen, or upper arm comfortable, rotating locations weekly to prevent injection site reactions.
BMI Monitoring Throughout Your Wegovy Journey
Meeting the initial BMI for Wegovy requirements is just the beginning of your weight management journey. Regular BMI monitoring helps track progress and adjust lifestyle interventions alongside your weekly injections. Many patients qualifying with BMI 30-35 see significant improvements in weight-related health conditions as their BMI reduces. Those who started with BMI 27 plus comorbidities often find their diabetes management, blood pressure, or sleep apnoea symptoms improve alongside BMI reduction.
Your ongoing BMI measurements provide valuable feedback about Wegovy's effectiveness when combined with the required reduced-calorie diet and increased physical activity. EverydayMeds provides continued support as your BMI changes, with our clinical team available to discuss dose adjustments, side effect management, and long-term treatment planning throughout your Wegovy journey.
Start Your Wegovy Treatment Today - From BMI Assessment To Delivery
Don't let confusion about BMI for Wegovy requirements delay your weight management goals. New customers save with discount code FIRST40, bringing your starter 0.25mg pen to just £79.99 including clinical assessment and specialist prescriber review. Returning customers use code DOSE25 for continued savings on their weight loss journey. Our GPhC-registered pharmacy (#9012878) ensures you receive genuine prescription-only medicine with full clinical support. Complete your BMI assessment and clinical questionnaire at https://everydaymeds.co.uk/collections/wegovy today, with most approvals processed within 3 working days. Join thousands of UK patients who've successfully started their Wegovy treatment through our trusted online service, backed by specialist clinical expertise and next-day delivery convenience.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
